Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single‐center phase I/II trial

Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single‐center phase I/II trial

The prognosis of patients with advanced pancreatic cancer is poor. In the present phase I/II study, we have evaluated the safety and the feasibility of Wilms' tumor 1 (WT1) and/or mucin1 (MUC1) peptide‐pulsed dendritic cell (DC) vaccination in combination with chemotherapy in patients with adva...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Therapeutic apheresis and dialysis 2021-08, Vol.25 (4), p.415-424
Hauptverfasser: Ogasawara, Masahiro, Miyashita, Mamiko, Yamagishi, Yuka, Ota, Shuichi
Format: Artikel
Sprache:eng
Schlagworte:
dendritic cell vaccination
gemcitabine
MUC1
pancreatic ductal adenocarcinoma
S‐1
WT1
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 424
container_issue 4
container_start_page 415
container_title Therapeutic apheresis and dialysis
container_volume 25
creator Ogasawara, Masahiro
Miyashita, Mamiko
Yamagishi, Yuka
Ota, Shuichi
description The prognosis of patients with advanced pancreatic cancer is poor. In the present phase I/II study, we have evaluated the safety and the feasibility of Wilms' tumor 1 (WT1) and/or mucin1 (MUC1) peptide‐pulsed dendritic cell (DC) vaccination in combination with chemotherapy in patients with advanced or relapsed pancreatic ductal adenocarcinoma (PDAC). Sixty‐five eligible patients were enrolled. No severe adverse events related to the vaccinations were observed. Objective response rate and disease control rate was 12.3% and 50.8%, respectively. Median progression‐free survival and overall survival were 4.9 and 9.6 months, respectively. DC vaccinations augmented WT1‐ and MUC1‐specific immunity which might be related to clinical outcome. These results indicate that DC‐based immunotherapy combined with a conventional chemotherapy is safe and feasible for patients in advanced stage of PDAC.
doi_str_mv 10.1111/1744-9987.13659
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2516844485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2516844485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3679-4d823a436c4f0116b4b4d931247a4db953919c4d8b1d39c5b09f282cbeb2e1b83</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxi1ERUvhzA35yGW7cez8MbeqUFipUntoz9bYnrBGiR3s7FZ74xF4lD4TT4JDyl7xZcae7_uN5I-Qd6y4YPmsWSPESsq2uWC8ruQLcnZ8eXnsG3lKXqf0vSjKUnD-ipxy3rY1q-oz8vQJvY1ucoYa7Hu6B2Och8kFT00YtPNo6aObthTy3e_RzyPoqdniEKYtRhgPtAuRjtmUp2lRR-xhTNmbJ2D34E3ux1wiwrzM7syUKWDRBwMx7wwDfMxLkvPfevz985fJMMzYLSSkm_VmQ6fooH9DTjroE759rufk4frz_dXX1c3tl83V5c3K8LqRK2HbkoPgtRFdwVithRZWclaKBoTVsuKSSZNVmlkuTaUL2ZVtaTTqEplu-Tn5sHDHGH7sME1qcGn-IvAYdkmVFatbIURbZel6kZoYUorYqTG6AeJBsULNMak5CDWHov7GlB3vn-E7PaA96v_lkgXVInh0PR7-x1P3l3cL-A8WuqFv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2516844485</pqid></control><display><type>article</type><title>Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single‐center phase I/II trial</title><source>Access via Wiley Online Library</source><creator>Ogasawara, Masahiro ; Miyashita, Mamiko ; Yamagishi, Yuka ; Ota, Shuichi</creator><creatorcontrib>Ogasawara, Masahiro ; Miyashita, Mamiko ; Yamagishi, Yuka ; Ota, Shuichi</creatorcontrib><description>The prognosis of patients with advanced pancreatic cancer is poor. In the present phase I/II study, we have evaluated the safety and the feasibility of Wilms' tumor 1 (WT1) and/or mucin1 (MUC1) peptide‐pulsed dendritic cell (DC) vaccination in combination with chemotherapy in patients with advanced or relapsed pancreatic ductal adenocarcinoma (PDAC). Sixty‐five eligible patients were enrolled. No severe adverse events related to the vaccinations were observed. Objective response rate and disease control rate was 12.3% and 50.8%, respectively. Median progression‐free survival and overall survival were 4.9 and 9.6 months, respectively. DC vaccinations augmented WT1‐ and MUC1‐specific immunity which might be related to clinical outcome. These results indicate that DC‐based immunotherapy combined with a conventional chemotherapy is safe and feasible for patients in advanced stage of PDAC.</description><identifier>ISSN: 1744-9979</identifier><identifier>EISSN: 1744-9987</identifier><identifier>DOI: 10.1111/1744-9987.13659</identifier><identifier>PMID: 33886156</identifier><language>eng</language><publisher>Kyoto, Japan: John Wiley &amp; Sons Australia, Ltd</publisher><subject>dendritic cell vaccination ; gemcitabine ; MUC1 ; pancreatic ductal adenocarcinoma ; S‐1 ; WT1</subject><ispartof>Therapeutic apheresis and dialysis, 2021-08, Vol.25 (4), p.415-424</ispartof><rights>2021 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3679-4d823a436c4f0116b4b4d931247a4db953919c4d8b1d39c5b09f282cbeb2e1b83</citedby><cites>FETCH-LOGICAL-c3679-4d823a436c4f0116b4b4d931247a4db953919c4d8b1d39c5b09f282cbeb2e1b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1744-9987.13659$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1744-9987.13659$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33886156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ogasawara, Masahiro</creatorcontrib><creatorcontrib>Miyashita, Mamiko</creatorcontrib><creatorcontrib>Yamagishi, Yuka</creatorcontrib><creatorcontrib>Ota, Shuichi</creatorcontrib><title>Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single‐center phase I/II trial</title><title>Therapeutic apheresis and dialysis</title><addtitle>Ther Apher Dial</addtitle><description>The prognosis of patients with advanced pancreatic cancer is poor. In the present phase I/II study, we have evaluated the safety and the feasibility of Wilms' tumor 1 (WT1) and/or mucin1 (MUC1) peptide‐pulsed dendritic cell (DC) vaccination in combination with chemotherapy in patients with advanced or relapsed pancreatic ductal adenocarcinoma (PDAC). Sixty‐five eligible patients were enrolled. No severe adverse events related to the vaccinations were observed. Objective response rate and disease control rate was 12.3% and 50.8%, respectively. Median progression‐free survival and overall survival were 4.9 and 9.6 months, respectively. DC vaccinations augmented WT1‐ and MUC1‐specific immunity which might be related to clinical outcome. These results indicate that DC‐based immunotherapy combined with a conventional chemotherapy is safe and feasible for patients in advanced stage of PDAC.</description><subject>dendritic cell vaccination</subject><subject>gemcitabine</subject><subject>MUC1</subject><subject>pancreatic ductal adenocarcinoma</subject><subject>S‐1</subject><subject>WT1</subject><issn>1744-9979</issn><issn>1744-9987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkc9u1DAQxi1ERUvhzA35yGW7cez8MbeqUFipUntoz9bYnrBGiR3s7FZ74xF4lD4TT4JDyl7xZcae7_uN5I-Qd6y4YPmsWSPESsq2uWC8ruQLcnZ8eXnsG3lKXqf0vSjKUnD-ipxy3rY1q-oz8vQJvY1ucoYa7Hu6B2Och8kFT00YtPNo6aObthTy3e_RzyPoqdniEKYtRhgPtAuRjtmUp2lRR-xhTNmbJ2D34E3ux1wiwrzM7syUKWDRBwMx7wwDfMxLkvPfevz985fJMMzYLSSkm_VmQ6fooH9DTjroE759rufk4frz_dXX1c3tl83V5c3K8LqRK2HbkoPgtRFdwVithRZWclaKBoTVsuKSSZNVmlkuTaUL2ZVtaTTqEplu-Tn5sHDHGH7sME1qcGn-IvAYdkmVFatbIURbZel6kZoYUorYqTG6AeJBsULNMak5CDWHov7GlB3vn-E7PaA96v_lkgXVInh0PR7-x1P3l3cL-A8WuqFv</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Ogasawara, Masahiro</creator><creator>Miyashita, Mamiko</creator><creator>Yamagishi, Yuka</creator><creator>Ota, Shuichi</creator><general>John Wiley &amp; Sons Australia, Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202108</creationdate><title>Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single‐center phase I/II trial</title><author>Ogasawara, Masahiro ; Miyashita, Mamiko ; Yamagishi, Yuka ; Ota, Shuichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3679-4d823a436c4f0116b4b4d931247a4db953919c4d8b1d39c5b09f282cbeb2e1b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>dendritic cell vaccination</topic><topic>gemcitabine</topic><topic>MUC1</topic><topic>pancreatic ductal adenocarcinoma</topic><topic>S‐1</topic><topic>WT1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogasawara, Masahiro</creatorcontrib><creatorcontrib>Miyashita, Mamiko</creatorcontrib><creatorcontrib>Yamagishi, Yuka</creatorcontrib><creatorcontrib>Ota, Shuichi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic apheresis and dialysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogasawara, Masahiro</au><au>Miyashita, Mamiko</au><au>Yamagishi, Yuka</au><au>Ota, Shuichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single‐center phase I/II trial</atitle><jtitle>Therapeutic apheresis and dialysis</jtitle><addtitle>Ther Apher Dial</addtitle><date>2021-08</date><risdate>2021</risdate><volume>25</volume><issue>4</issue><spage>415</spage><epage>424</epage><pages>415-424</pages><issn>1744-9979</issn><eissn>1744-9987</eissn><abstract>The prognosis of patients with advanced pancreatic cancer is poor. In the present phase I/II study, we have evaluated the safety and the feasibility of Wilms' tumor 1 (WT1) and/or mucin1 (MUC1) peptide‐pulsed dendritic cell (DC) vaccination in combination with chemotherapy in patients with advanced or relapsed pancreatic ductal adenocarcinoma (PDAC). Sixty‐five eligible patients were enrolled. No severe adverse events related to the vaccinations were observed. Objective response rate and disease control rate was 12.3% and 50.8%, respectively. Median progression‐free survival and overall survival were 4.9 and 9.6 months, respectively. DC vaccinations augmented WT1‐ and MUC1‐specific immunity which might be related to clinical outcome. These results indicate that DC‐based immunotherapy combined with a conventional chemotherapy is safe and feasible for patients in advanced stage of PDAC.</abstract><cop>Kyoto, Japan</cop><pub>John Wiley &amp; Sons Australia, Ltd</pub><pmid>33886156</pmid><doi>10.1111/1744-9987.13659</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1744-9979
ispartof Therapeutic apheresis and dialysis, 2021-08, Vol.25 (4), p.415-424
issn 1744-9979
1744-9987
language eng
recordid cdi_proquest_miscellaneous_2516844485
source Access via Wiley Online Library
subjects dendritic cell vaccination
gemcitabine
MUC1
pancreatic ductal adenocarcinoma
S‐1
WT1
title Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single‐center phase I/II trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T09%3A27%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dendritic%20cell%20vaccination%20combined%20with%20a%20conventional%20chemotherapy%20for%20patients%20with%20relapsed%20or%20advanced%20pancreatic%20ductal%20adenocarcinoma:%20a%20single%E2%80%90center%20phase%20I/II%20trial&rft.jtitle=Therapeutic%20apheresis%20and%20dialysis&rft.au=Ogasawara,%20Masahiro&rft.date=2021-08&rft.volume=25&rft.issue=4&rft.spage=415&rft.epage=424&rft.pages=415-424&rft.issn=1744-9979&rft.eissn=1744-9987&rft_id=info:doi/10.1111/1744-9987.13659&rft_dat=%3Cproquest_cross%3E2516844485%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2516844485&rft_id=info:pmid/33886156&rfr_iscdi=true